

Patent  
Attorney Docket: 259/058

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

LIPTON, James M et al.

Serial No.: 09/828,272

Filed: April 6, 2001

For: USE Of KPV TRIPEPTIDE FOR  
DERMATOLOGICAL DISORDERS



Group Art Unit: 1646

Examiner: not yet assigned

RECEIVED

JUN 07 2002

TECH CENTER 1600/2900

TRANSMITTAL OF SEQUENCE LISTING

Box Sequence  
Commissioner for Patents  
Washington, D.C. 20231

Sir:

I. DOCUMENTS ENCLOSED:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed by the Patent Office on November 15, 2001, enclosed are:

- A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Submission of Sequence Listing with both paper and computer-readable copies of the sequence listing;
- Petition for Extension of Time Under 37CFR 1.36(a); and
- Return receipt-acknowledgment postcard.


LA-223060.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Miyabi Grace

Name of Person Mailing Paper



Signature of Person Mailing Paper

January 28, 2002

Date of Deposit

**II. PAYMENT:**


No fee is required for this request. If Applicants are mistaken, however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Lyon & Lyon's Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: 1/28/02

By:



Michael J. Wise  
Reg. No. 34,047



**22249**

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071  
Tel: (213) 489-1600  
Fax: (213) 955-0440

RECEIVED



UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 17 2002

TECH CENTER 1000/2000

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/828,272	04/06/2001	James M. Lipton	259/058

22249  
LYON & LYON LLP  
633 WEST FIFTH STREET  
SUITE 4700  
LOS ANGELES, CA 90071



CONFIRMATION NO. 6351

FORMALITIES LETTER



\*OC00000007072450\*

Date Mailed: 11/15/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

---

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED

JUN 07 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/828,272	04/06/2001	James M. Lipton	259/058

22249  
 LYON & LYON LLP  
 633 WEST FIFTH STREET  
 SUITE 4700  
 LOS ANGELES, CA 90071



CONFIRMATION NO. 6351  
**FORMALITIES LETTER**



\*OC00000008034819\*

Date Mailed: 05/06/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*of Jm*  
*A copy of this notice MUST be returned with the reply.*

---

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

LIPTON, James M et al.

Serial No.: 09/828,272

Filed: April 6, 2001

For: USE Of KPV TRIPEPTIDE FOR  
DERMATOLOGICAL DISORDERS



) Group Art Unit: 1646

) Examiner: not yet assigned

JUN 07 2002

TECH CENTER 1600/2900

RECEIVED

SUBMISSION OF SEQUENCE LISTING


U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed are a computer readable copy and a paper copy of the Sequence Listing for the above-identified patent application. The contents of both the computer readable and the paper copies are the same and, where applicable, include no new matter, as required by 37 §§ CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

Respectfully submitted,  
LYON & LYON LLP

By:

  
Michael J. Wise  
Reg. No. 34,047

Dated: 5/28/02



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071  
Phone: (213) 489-1600  
Fax: (213) 955-0440

LA-236642.1


CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

MAY 28, 2002  
Date of Deposit

MIYABI GRACE

Name of Person Mailing Paper

  
Signature of Person Mailing Paper



1646

Patent  
Attorney Docket: 259/058

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

LIPTON, James M et al.

Serial No.: 09/828,272

Filed: April 6, 2001

For: USE Of KPV TRIPEPTIDE FOR  
DERMATOLOGICAL DISORDERS

) Group Art Unit: 1646

) Examiner: not yet assigned

TECH CENTER 1600/2900  
JUN 07 2002

RECEIVED

## TRANSMITTAL OF SEQUENCE LISTING

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed by the Patent Office on May 6, 2002, enclosed are:

- Submission of Sequence Listing with sequence listing in paper and computer readable forms
- Copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- Copy of Transmittal of Sequence Listing filed on January 28, 2002, including Petition for Extension of Time Under 37CFR 1.36(a); and
- Return receipt-acknowledgment postcard.

LA-236639.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Miyabi Grace

Name of Person Mailing Paper

MAY 28, 2002

Date of Deposit

Miyabi Grace  
Signature of Person Mailing Paper

Patent  
Attorney Docket: 259/058


No fee is required for this request. If Applicants are mistaken, however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Lyon & Lyon's Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: 5/28/02

By:

  
Michael J. Wise  
Reg. No. 34,047



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071  
Tel: (213) 489-1600  
Fax: (213) 955-0440

## CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/828,272  
Filing Date: 4-6-2001  
Date Processed by STIC: 3-4-2002

STIC Contact: Mark Spencer, 703-308-4212

### Nature of Problem:

The CRF (was):

(circle one) Damaged or Unreadable (for Unreadable, see attached)  
 Blank (no files on CRF) (see attached)  
 Empty file (filename present, but no bytes in file) (see attached)  
 Virus-infected. Virus name: \_\_\_\_\_ The STIC will not process the CRF.  
 Not saved in ASCII text  
 Sequence Listing was embedded in the file. According to Sequence Rules,  
submitted file should only be the Sequence Listing.  
 Did not contain a Sequence Listing. (see attached sample)  
 Other:

**PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.**

**SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name,  
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,  
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,  
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



**RECEIVED**

MAR 13 2002

TECH CENTER 1600/2900

**RECEIVED**

JUN 07 2002

TECH CENTER 1600/2900

BEST AVAILABLE COPY

